Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1471 to 1485 of 7707 results

  1. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

    Evidence-based recommendations on docetaxel for treating hormone-refractory metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    28 June 2006
    View recommendations

    Sections for TA101

  2. Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)

    Evidence-based recommendations on capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer in adults.

    Technology appraisal guidance
    Published
    26 April 2006
    View recommendations

    Sections for TA100

  3. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

    Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.

    Technology appraisal guidance
    Published
    22 February 2006
    View recommendations

    Sections for TA96

  4. HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) (TA92)

    Evidence-based recommendations on using an ozone-releasing device (HealOzone) in people with tooth decay.

    Technology appraisal guidance
    Published
    27 July 2005
    View recommendations

    Sections for TA92

  5. Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)

    Evidence-based recommendations on paclitaxel for treating ovarian cancer in adults.

    Technology appraisal guidance
    Last updated
    1 May 2005
    View recommendations

    Sections for TA55

  6. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA195

  7. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.

    Technology appraisal guidance
    Published
    26 January 2016
    View recommendations

    Sections for TA375

  8. Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    9 March 2022
    View recommendations

    Sections for TA773

  9. Frequency of application of topical corticosteroids for atopic eczema (TA81)

    Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.

    Technology appraisal guidance
    Published
    25 August 2004
    View recommendations

    Sections for TA81

  10. Tacrolimus and pimecrolimus for atopic eczema (TA82)

    Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.

    Technology appraisal guidance
    Published
    25 August 2004
    View recommendations

    Sections for TA82

  11. Laparoscopic surgery for inguinal hernia repair (TA83)

    Evidence-based recommendations on laparoscopic surgery for treating inguinal hernia.

    Technology appraisal guidance
    Published
    22 September 2004
    View recommendations

    Sections for TA83

  12. Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

    Evidence-based recommendations on using thrombolytic drugs (alteplase [Actilyse], reteplase [Rapilysin], streptokinase [Streptase] and tenecteplase [Metalyse]) for treating acute myocardial infarction in adults.

    Technology appraisal guidance
    Published
    30 October 2002
    View recommendations

    Sections for TA52

  13. Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding (TA78)

    Evidence-based recommendations on fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding in adults.

    Technology appraisal guidance
    Published
    28 April 2004
    View recommendations

    Sections for TA78

  14. Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

    Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital.

    Technology appraisal guidance
    Published
    28 January 2004
    View recommendations

    Sections for TA74

  15. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77)

    Evidence-based recommendations on zolpidem and zopiclone for treating insomnia in adults.

    Technology appraisal guidance
    Published
    28 April 2004
    View recommendations

    Sections for TA77